End-of-Life Costs in Cancer Patients: A Systematic Review
Authors:
- Soraya Camargo Ito SüffertSSSoraya Camargo Ito Süffert
- Carlos Eduardo Aliatti ManteseCMCarlos Eduardo Aliatti Mantese
- Felipe Rodrigo de Castro MeiraFMFelipe Rodrigo de Castro Meira
- Katia Flavia Rosso de Oliveira TrindadeKTKatia Flavia Rosso de Oliveira Trindade
- Ana Paula Beck da Silva EtgesAna Paula Beck da Silva Etges
- Rafael José Vargas AlvesRARafael José Vargas Alves
- Claudia Giuliano BicaCBClaudia Giuliano Bica
- 23 September 2024
- journal article
- research article
- Published by SAGE Publications in American Journal of Hospice and Palliative Medicine®
- Vol. 42 (9) , 932-961
Abstract
Objectives: Identify the costs of an oncology patient at the end of life. Methods: A systematic literature review was conducted by screening Embase, PubMed and Lilacs databases, including all studies evaluating end-of-life care costs for cancer patients up to March 2024. The review writing followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The quality of the included studies was assessed using the Drummond checklist. The protocol is available at PROSPERO CRD42023403186. Results: A total of 733 studies were retrieved, and 43 were considered eligible. Among the studies analyzed, 41,86% included all types of neoplasms, 18.60% of lung neoplasm, All articles performed direct cost analysis, and 9.30% also performed indirect cost analysis. No study evaluated intangible costs, and most presented the macrocosting methodology from the payer’s perspective. The articles included in this review presented significant heterogeneity related to populations, diagnoses, periods considered for evaluation of end-of-life care, and cost analyses. Most of the studies were from a payer perspective (74,41%) and based on macrocosting methodologies (81,39%), which limit the use of the information to evaluate variabilities in the consumption of resources. Conclusions: Considering the complexity of end-of-life care and the need for consistent data on costs in this period, new studies, mainly in low- and middle-income countries with approaches to indirect and intangible costs, with a societal perspective, are important for public policies of health in accordance with the trend of transforming value-based care, allowing the health care system to create more value for patients and their families.Keywords
This publication has 58 references indexed in Scilit:
- Why is end‐of‐life inpatient cost high among cancer patients? A prospective cohort studyCancer Medicine, 2024
- Estimates and Projections of the Global Economic Cost of 29 Cancers in 204 Countries and Territories From 2020 to 2050JAMA Oncology, 2023
- Medicare Spending, Utilization, and Quality in the Oncology Care ModelJAMA, 2021
- Disparities in Care Management During Terminal Hospitalization Among Adults With Metastatic Cancer From 2010 to 2017JAMA Network Open, 2021
- Inpatient utilization and disparities: The last year of life of adolescent and young adult oncology patients in CaliforniaCancer, 2018
- Association between survival time with metastatic breast cancer and aggressive end-of-life careBreast Cancer Research and Treatment, 2017
- Comparison of Site of Death, Health Care Utilization, and Hospital Expenditures for Patients Dying With Cancer in 7 Developed CountriesJAMA, 2016
- Impact of aggressive management and palliative care on cancer costs in the final month of lifeCancer, 2015
- Health economics of a palliative care unit for terminal cancer patients: a retrospective cohort studySupportive Care in Cancer, 2010
- Cost Savings Associated With US Hospital Palliative Care Consultation ProgramsArchives of internal medicine (1960), 2008